{
  "title": "M21-1, Part V, Subpart iii, Chapter 10 - Skin Conditions",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180515/M21-1-Part-V-Subpart-iii-Chapter-10-Skin-Conditions",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Chapter\nThis chapter contains the following topics:\nTopic\nTopic Name\n1\nGeneral Principles for Rating Skin Disorders and Scars\n2\nRating Scars or Other Disfigurement of the Head, Face, or Neck\n3\nRating Painful or Unstable Scars\n4\nRating Specific Skin Conditions\n1\n.\nGeneral Principles for Rating Skin Disorders and Scars\nIntroduction\nThis topic contains general principles for rating skin disorders and scars, including\napplying alterative rating criteria in evaluating skin conditions\nseparate evaluations for multiple skin disorders using the general rating formula\nexample of separate evaluations using the general rating formula\nseparate evaluation using the general rating formula based on medication criteria\nsingle evaluations using the general rating formula for multiple skin disorders\nsystemic therapy such as corticosteroids or other immunosuppressive drugs\nexposed body area\napplication of the bilateral factor for skin conditions to include scarring\n, and\nrevisions of the skin rating schedule\n.\nChange Date\nNovember 19, 2018\nV.iii.10.1.a\n.\nApplying Alternative Rating Criteria in Evaluating Skin Conditions\nWhen\n38 CFR 4.118\noffers variable methods to evaluate a skin condition, assign a single evaluation using the criteria that results in the highest rating.\nExample\n:  Under\n38 CFR 4.118 diagnostic code (DC) 7806\n, dermatitis is to be rated using the general rating formula for the skin.  Within the general rating formula, skin conditions are rated on either skin involvement/type of treatment or as disfigurement of the head, face, or neck or scars, depending upon the predominant disability.  For examination findings of dermatitis involving at least 5 percent, but less than 20 percent, of the entire body (a 10-percent evaluation under\n38 CFR 4.118 DC 7806\n) and scarring that is noncompensable under\n38 CFR 4.118 DC 7800\nthrough\n38 CFR 4.118 DC 7805\n, a single evaluation of 10 percent is warranted under\n38 CFR 4.118 DC 7806\n.  Assigning an evaluation for dermatitis based on percentage of involvement of the entire body and a separate evaluation based on the residual scarring amounts to pyramiding.\nReference\n:  For more information on avoidance of pyramiding, see\n38 CFR 4.14\n, and\nM21-1, Part V, Subpart ii, 3.D.2.b\n.\nV.iii.10.1.b\n.\nSeparate Evaluations for Multiple Skin Disorders Using the General Rating Formula\nWhen evaluating separately diagnosed skin conditions and the predominant disability requires evaluation under the general rating formula for the skin, separate evaluations for each diagnosis are permissible when the evaluation is based on disability due solely to the individual diagnosis.\nHowever, when it is most advantageous and allows for maximized benefits, multiple skin disorders evaluated under the same criteria may be assigned a single disability evaluation as discussed in\nM21-1, Part V, Subpart iii, 10.1.e\n.\nV.iii.10.1.c\n.\nSeparate Evaluations Using the General Rating Formula\nA Veteran diagnosed with multiple skin conditions may receive separate evaluations using the general rating formula for the skin based on the percentage of exposed areas affected by each skin condition when\nseparate areas of skin are involved, and\nthe medical evidence clearly indicates that the percentages affected are due solely to each individual diagnosis.\nExample\n:  The medical evidence clearly indicates that skin condition X alone affects 6 percent of the exposed skin, while skin condition Y alone affects 12 percent of the exposed skin.  The area affected by each skin disability is entirely separate.  In this scenario, separate evaluations may be assigned.\nImportant\n:\nThe evidence\nmust\nidentify which residual disability is due to which individual skin condition.\nIt may be necessary to request clarification from an examiner to identify the percentage of exposed skin affected only by one skin condition versus the other skin condition.\nIf an examiner cannot provide separate percentages due solely to each skin condition, separate evaluations cannot be granted using those criteria alone.  If two or more skin conditions involve the same area of skin, assign the highest evaluation based on the combined area of involvement.\nThis guidance applies equally to evaluations based on the percentage of the entire body affected as well.\nReference\n:  For more information on assigning a single evaluation for multiple skin disabilities in order to maximize benefits, see\nM21-1, Part V, Subpart iii, 10.1.e\n.\nV.iii.10.1.d\n.\nSeparate Evaluations Using the General Rating Formula Based on Medication Criteria\nIf the same medication(s) is/are used to treat each skin condition, separate evaluations may not be assigned unless alternative criteria are used to establish the disability evaluation for the separately evaluated skin condition(s) and separate areas of the skin are affected.\nExample\n:  The Veteran has dermatitis of the neck involving at least 5 percent but less than 20 percent of exposed body area.  The Veteran also has psoriasis on the knees involving less than 5 percent of total body area.  Both conditions were treated with oral corticosteroids for a period of less than 6 weeks over the past 12-month period.  Separate 10-percent disability evaluations may be assigned.  Assign a 10-percent evaluation for dermatitis based on exposed area affected, and assign a separate 10-percent evaluation for psoriasis treated with oral steroids\n.\nImportant\n:  The decision maker should assign separate evaluations in a manner that provides the most advantageous rating for the Veteran.\nV.iii.10.1.e\n.\nSingle Evaluations Using the General Rating Formula for Multiple Skin Disorders\nA Veteran diagnosed with multiple skin conditions that are evaluated using the general rating formula for the skin based on the percentage of total body area or exposed areas affected may receive a single evaluation when\nevaluating the disabilities together allows for maximization of benefits, or\nthe symptoms of and/or area affected by the multiple disabilities cannot be separated, as is directed by\n38 CFR 4.14\n.\nExample 1\n:\nA Veteran has service-connected (SC) dermatitis that affects areas of the arms, covering 10 percent of the entire body area.  The Veteran also has SC tinea corporis affecting the groin and upper legs, covering 10 percent of the entire body area.  Different topical medications are used to treat each disability.  Evaluated individually, each skin disorder warrants a separate 10-percent evaluation under the general rating formula for the skin.  As the disabilities combine to affect a total 20 percent of the entire body and do not affect the same area of the body, a single 30-percent evaluation for dermatitis and tinea corporis may be assigned under\n38 CFR 4.118, DC 7806-7813\n.  In this case, the single evaluation is assigned to maximize benefits since assignment of separate 10-percent evaluations would be a lesser benefit.\nExample 2\n:  A Veteran has SC dermatitis and eczema.  Both disabilities affect the hands, covering a total of three percent of exposed body area.  The examiner is unable to differentiate the percent of body area affected by each disorder.  The same topical treatment is used for both conditions.  A single zero percent disability evaluation must be assigned since the evaluation of the same manifestation under different diagnoses must be avoided.\nNotes\n:\nWhen the Veteran has multiple SC skin disorders and maximization of benefits via assignment of a single evaluation appears possible but the examination results do not provide the specific measurements of affected body area, request a medical opinion to determine the actual percentage of body area affected.\nWhen analysis shows that benefits maximization is possible with the assignment of a single disability evaluation, enter the disabilities as a single disorder in the Evaluation Builder.  For example, using the facts from\nExample 1\nabove, choose the predominant diagnosis and enter the single 20-percent finding for the percentage of body area affected.  This Evaluation Builder workaround must be utilized until updates are made for this functionality.\nV.iii.10.1.f\n.\nSystemic Therapy Such as Corticosteroids or Other Immunosuppressive Drugs\nThe term systemic therapy that is contained in the general rating formula for the skin and in certain additional DCs under\n38 CFR 4.118\nrefers to treatment that is administered through any route (orally, injection, suppository, intranasally) other than the skin. Medications that are applied topically (directly to the skin), including topical corticosteroids or immunosuppressives, are not considered systemic for Department of Veterans Affairs (VA) purposes.\nNotes\n:\nWhen there is a question as to whether drug treatment is systemic therapy for rating purposes, request clarification from a VA or other licensed medical professional.\nThe changes to\n38 CFR 4.118\neffective on August 13, 2018, preclude any consideration of topical therapy, irrespective of the extent of application to the body, as systemic therapy.\nFor claims filed prior to August 13, 2018, where the skin condition is evaluated under the\nhistorical 38 CFR 4.118\n, medications that are applied topically (directly to the skin), including topical corticosteroids or immunosuppressives, are generally not considered systemic for VA purposes.  Under the historical rating criteria, a topical corticosteroid may only be considered systemic therapy where it is administered on such a large scale over the body that it affects the body as a whole.\nIf the evidence suggests that a skin disability is treated so extensively with a topical corticosteroid that it may be consistent with systemic therapy, refer the case to an appropriate dermatology specialist for an opinion addressing whether the topical corticosteroid is used so extensively on the body that it may be considered systemic therapy.\nIf the matter cannot be resolved after obtaining the medical opinion, refer the case to Compensation Service for an advisory opinion.\nExample\n:  A Veteran is SC for dermatitis herpetiformis. Medical evidence shows she was treated with oral Dapsone for 7 weeks during the past 12-month period.  An evaluation of 30 percent is warranted for treatment with systemic therapy for a total duration of six weeks or more, but not constantly, during the past 12-month period.\nReferences\n:  For more information on\nthe meaning of “such as” in the rating schedule, see\nMauerhan v. Principi\n, 16 Vet.App. 436 (2002), and\ndetermining whether topical corticosteroids can be considered systemic under historical rating criteria, see\nJohnson v. Shulkin\n, 862 F.3d 1351 (2017), and\nBurton v. Wilkie\n, No. 16-2307 (2018), and\nrequesting advisory opinions, see\nM21-1, Part X, Subpart v, 1.A.2\n.\nV.iii.10.1.g\n.\nExposed Body Area\nWhen evaluating disabilities under\n38 CFR 4.118\n,\nexposed areas\nas referenced in evaluation criteria refer to the face, neck, and hands.\nV.iii.10.1.h\n.\nApplication of the Bilateral Factor to Evaluations for Skin Conditions to Include Scarring\nThe bilateral factor under\n38 CFR 4.26\nonly applies to skin conditions rated based on the skin evaluation criteria under\n38 CFR 4.118, DCs 7801 or 7802\nas the evaluation criteria and notes provided by these DCs specifically address entitlement to separate evaluations for multiple extremity involvement.  The bilateral factor may also be for application for conditions rated under a DC with evaluation criteria not considering skin involvement (such as when the predominant disability is that pertaining to musculoskeletal impairment).  Do not apply the bilateral factor to DCs for skin conditions to include scars that are\nbased on whole-body involvement\nbased on number of debilitating episodes, or\nspecific to the head, face, and/or neck.\nExamples\n:\nThe bilateral factor is not for application to\n38 CFR 4.118, DC 7804\nas painful or unstable scars are not evaluated separately under this DC.\nFor ratings based on malignant skin neoplasms under\n38 CFR 4.118, DC 7818\n, the bilateral factor is not for application when assigning a 100 percent evaluation for active malignancy/treatment for six months following cessation.  However, when evaluating based on residuals following the six-month period, the bilateral factor may or may not apply depending on whether the residual is being evaluated based on a qualifying DC.\nV.iii.10.1.i\n.\nRevisions of the Skin Rating Schedule\nRegulatory revisions to the rating schedule are generally not liberalizing, including those revisions to\n38 CFR 4.118\neffective on October 23, 2008, and August 13, 2018.\n38 CFR 3.114(a)\ndoes not apply because the regulatory change did not characterize the change as a liberalizing change of law or VA issue.\nReference\n:  For more information on assigning effective dates based on regulatory updates to the rating schedule, see\nM21-1, Part V, Subpart ii, 4.A.6\n.\n2\n.\nRating Scars or Other Disfigurement of the Head, Face, or Neck\nIntroduction\nThis topic contains information on rating scars or other disfigurement of the head, face, or neck, including\nconsidering color photographs in evaluating scars or other disfigurement\nevaluating\nmultiple scars\n, and\ntissue loss of the auricle, anatomical loss of the eye, and other disabling effects\n, and\nwhether scars or disfigurement of the head, face, or neck are part of the claim\n.\nChange Date\nAugust 13, 2018\nV.iii.10.2.a\n.\nConsidering Color Photographs in Evaluating Scars or Other Disfigurement\nWhen an examination report indicates that photographs have been taken of a scar or skin condition, consider the photographs when evaluating the condition.\nReference\n:  For more information on procedures for handling photographs associated with skin and scars examinations, see\nM21-1, Part IV, Subpart i, 3.B.1.k\n.\nV.iii.10.2.b\n.\nEvaluating Multiple Scars\nScars of the head, face, or neck are evaluated based on characteristics of disfigurement.  For all characteristics of disfigurement included in\n38 CFR 4.118, DC 7800\nthat are evaluated based on size of area affected, the area affected by multiple scars may be added together to meet the total area criteria for the characteristic of disfigurement.  The characteristics of disfigurement criteria that can be met by adding the area affected by multiple scars include\nlength\nhypo- or hyper-pigmentation\nabnormal skin texture\nabsence of underlying soft tissue, and\ninduration or inflexibility.\nException\n:  Multiple scars may\nnot\nbe added together to meet the width of scarring requirement.\nExamples\n:\nTwo scars, one measuring two inches in length and the other measuring three inches in length, may be combined to meet the requirement of a scar five inches or more in length to qualify as a characteristic of disfigurement.\nIn contrast, two scars, one measuring .13 inches in width and the other measuring .12 inches in width, may not be combined to meet the requirement of a scar at least one-quarter inch wide at the widest part.\nReferences\n:  For more information on\nevaluating\nmultiple painful or unstable scars, see\n38 CFR 4.118, DC 7804\n, and\nmultiple burn or other scars not of the head, face, or neck, see\n38 CFR 4.118, DC 7801\n, Notes 1 and 2, and\n38 CFR 4.118, DC 7802\n, Notes 1 and 2.\nV.iii.10.2.c\n.\nEvaluating Tissue Loss of the Auricle, Anatomical Loss of the Eye, and Other Disabling Effects\nEvaluate tissue loss of the auricle under\n38 CFR 4.87, DC 6207\nand anatomical loss of the eye under\n38 CFR 4.79, DC 6061 or 6063\n,\nas appropriate.\nWhen the evidence of record shows disabling effects other than disfigurement, such as pain, instability, or muscle/nerve injury, separately evaluate under the appropriate DC based on the functional impairment shown by the record.\nReference\n:  For more information on evaluating scars and what qualifies as a characteristic of disfigurement, see\n38 CFR 4.118\n.\nV.iii.10.2.d\n.\nWhether Scars or Disfigurement of the Head, Face, or Neck Are Part of the Claim\nIf a scar or other disfigurement of the head, face, or neck is noted on VA examination or in other evidence of record but has not been expressly claimed, whether to put it at issue and decide it as part of the claim depends on whether\nthe scar is considered within scope of the pending claim\n.\nReferences\n:  For more information on\nwithin scope determinations\n, see\nM21-1, Part V, Subpart ii, 3.A.1.c\n, and\nsoliciting a claim for unclaimed chronic disabilities shown by the evidence, see\nM21-1, Part II, Subpart iii, 2.G.2\n.\n3\n.\nRating Painful or Unstable Scars\nIntroduction\nThis topic contains information on rating painful or unstable scars, including\nassigning a separate disability evaluation for functional impairment due to a painful scar\nobjective evidence of a painful scar\ndefinition of an unstable scar\nevaluating unstable and painful scars\n, and\nwhether painful or unstable scars are part of the claim\n.\nChange Date\nAugust 13, 2018\nV.iii.10.3.a\n.\nAssigning a Separate Disability Evaluation for Functional Impairment Due to a Painful Scar\nA separate disability evaluation for a painful scar under\n38 CFR 4.118, DC 7804\nmay be assigned when the evidence demonstrates functional impairment that is\ndistinct and separate from the functional impairment addressed by another DC, and is not\nduplicative of or overlapping with the symptomatology addressed under another DC.\nExample\n:  A separate 10-percent evaluation for disfigurement under\n38 CFR 4.118, DC 7800\nmay be assigned in addition to a 10-percent evaluation for painful scars under\n38 CFR 4.118, DC 7804\nand a 10-percent evaluation for facial injury interfering with mastication under\n38 CFR 4.73, DC 5325\nas each evaluation is based on distinct and separate functional impairment and, therefore, provisions related to pyramiding are not violated.\nNote\n:  An evaluation under\n38 CFR 4.118, DC 7800\nis entirely cosmetic in nature.\nReferences\n:  For more information on\nassigning a separate disability evaluation for functional impairment due to a painful scar, see\nEsteban v. Brown\n, 6 Vet.App. 259 (1994)\nevaluating scars in the presence of muscle conditions, see\nM21-1, Part V, Subpart iii, 1.E.2.h\n, and\npyramiding, see\n38 CFR 4.14\n, and\nM21-1, Part V, Subpart ii, 3.D.2.b\n.\nV.iii.10.3.b\n.\nObjective Evidence of a Painful Scar\nUnder\n38 CFR 4.118, DC 7804\n, an evaluation of 10 percent is assigned for one or two scars that are unstable\nor\npainful.\nDo not establish a compensable evaluation for a painful scar unless there is some objective indication supporting subjective reports of pain or tenderness.\nThe physical examination section (for the trunk/extremities or the head/face/ neck as applicable) of the\nScars/Disfigurement Disability Benefits Questionnaire\n(DBQ) asks the examiner if scars are tender to palpation and, if yes, to check the box.  If the examiner checks that a scar is tender to palpation consider pain to be objectively demonstrated.\nExample\n:  On VA examination, the Veteran gave a history of a painful scar of the trunk.  On the DBQ, in the physical examination of the trunk and extremities, the examiner checked that the trunk scar was tender to palpation.  Accept that the scar is objectively painful.\nExample\n:  On VA examination, the Veteran gave a history of a painful scar of the left arm.  On the DBQ, in the physical examination of the trunk and extremities, the examiner did not check that the scar was tender to palpation.  Do not accept that the scar is objectively painful.\nV.iii.10.3.c\n.\nDefinition:  Unstable Scar\nAn\nunstable scar\nis a scar in which, for any reason, there is frequent loss of covering of skin over the scar.\nReference\n:  For more information on unstable scars, see\n38 CFR 4.118, DC 7804\n.\nV.iii.10.3.d\n.\nEvaluating Unstable and Painful Scars\nWhen a scar is\nboth\nunstable and painful, add 10 percent to the evaluation that would otherwise be assigned based on the total number of unstable or painful scars under\n38 CFR 4.118, DC 7804\n.\nExample\n:  If a VA examination notes one right knee arthroscopy scar that is described as unstable and painful, the proper evaluation based on the painful and unstable scar is 20 percent.  Under\n38 CFR 4.118, DC 7804\n, one painful scar is entitled to an evaluation of 10 percent.  Since the painful scar is also noted to be unstable, an additional 10 percent is added to that evaluation to arrive at an overall evaluation of 20 percent.\nV.iii.10.3.e\n.\nWhether Painful or Unstable Scars Are Part of the Claim\nIf a painful or unstable scar is noted on VA examination or in other evidence of record but has not been expressly claimed, whether to put it at issue and decide it as part of the claim depends on whether the scar is considered within scope of the pending claim.\nReferences\n:  For more information on\nwithin scope determinations, see\nM21-1, Part V, Subpart ii, 3.A.1.c\n, and\nsoliciting a claim for unclaimed chronic disabilities shown by the evidence, see\nM21-1, Part II, Subpart iii, 2.G.2\n.\n4\n.\nRating Specific Skin Conditions\nIntroduction\nThis topic contains information on rating specific skin conditions, including\nSC for male pattern baldness or androgenetic alopecia\nassigning multiple evaluations due to hair loss\n, and\nevaluating mycosis fungoides\n.\nChange Date\nNovember 19, 2018\nV.iii.10.4.a\n.\nSC for Male Pattern Baldness or Androgenetic Alopecia\nDo not grant SC for\nmale pattern baldness, or\nandrogenetic alopecia.\nNote\n:  VA classifies these conditions as congenital or developmental abnormalities.\nImportant\n:  While SC is not warranted for alopecia of androgenetic origin, VA recognizes hair loss due to scarring alopecia and alopecia areata under\n38 CFR 4.118, DCs 7830 and 7831\n, as disabilities for which SC is warranted if first manifest in service.\nReference\n:  For more information on congenital or developmental abnormalities, see\n38 CFR 4.9\n, and\nM21-1, Part V, Subpart ii, 2.E\n.\nV.iii.10.4.b\n.\nAssigning Multiple Evaluations Due to Hair Loss\nAssign separate evaluations for\ncomplete loss of the eyebrows and eyelashes due to injury, burns, or local disease under\n38 CFR 4.79, DC 6023\ncomplete loss of the eyelashes due to injury, burns, or local disease under\n38 CFR 4.79, DC 6024\n, and\nloss of all body hair due to alopecia areata or an analogous condition under\n38 CFR 4.118, DC 7831\n.\nV.iii.10.4.c\n.\nEvaluating Mycosis Fungoides\nMycosis fungoides is a cutaneous manifestation of T-cell lymphoma that typically presents as some form of skin lesion and rarely progresses beyond the skin.\nFor rating purposes, it is not considered a systemic malignancy.  As such, with the revised skin rating schedule, mycosis fungoides should be evaluated under\n38 CFR 4.118, DC 7822\n.\nIf the condition progresses to a lymphoma with appropriate diagnosis, such as Non-Hodgkin’s lymphoma (active disease/active treatment phase), it would warrant an evaluation under\n38 CFR 4.118, DC 7715\n.\nNote\n:  Prior to the rating schedule change of August 13, 2018, mycosis fungoides was evaluated as\neither\na skin malignancy if manifestations were cutaneous lesions only and treatment was confined to only\nlocalized topical therapy, or\nsurgical excision (wide local excision or less extensive excision), or\nnon-Hodgkin’s lymphoma if manifestations were indicative of systemic disease with treatment consistent with systemic malignancy.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 11px\"><a articleid=\"554400000180513\" articlename=\"M21-1, Part V, Subpart iii, Chapter 9 - Hematologic and Lymphatic Systems\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180513/M21-1-Part-V-Subpart-iii-Chapter-9-Hematologic-and-Lymphatic-Systems\">&lt;-- Previous Section</a>  <a articleid=\"554400000180518\" articlename=\"M21-1, Part V, Subpart iii, Chapter 11 - Endocrine Conditions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180518/M21-1-Part-V-Subpart-iii-Chapter-11-Endocrine-Conditions\">Next Section --&gt;</a></span></span><span style=\"font-size: 16px\"><strong><span style=\"font-family: arial , helvetica , sans-serif\"> </span></strong></span></p><h2 class=\"ng-scope\"><a id=\"Top\" name=\"Top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><p class=\"ng-scope\"></p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Chapter</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This chapter contains the following topics:</span></span></div><div></div><div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\"><thead><tr><th scope=\"col\" style=\"width: 84px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\"><strong>Topic</strong></span></span></span></div></th><th scope=\"col\" style=\"width: 415px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\"><strong>Topic Name</strong></span></span></span></div></th></tr></thead><tbody><tr><td style=\"height: 0px; width: 84px; text-align: center; padding: 1px;\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\">1</span></span></span></td><td style=\"height: 0px; width: 415px; padding: 1px;\"><a href=\"#1\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">General Principles for Rating Skin Disorders and Scars</span></span></a></td></tr><tr><td style=\"height: 0px; width: 84px; text-align: center; padding: 1px;\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\">2</span></span></span></td><td style=\"height: 0px; width: 415px; padding: 1px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\">Rating Scars or Other Disfigurement of the Head, Face, or Neck</span></span></a></span></div></td></tr><tr><td style=\"height: 0px; width: 84px; text-align: center; padding: 1px;\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\">3</span></span></span></td><td style=\"height: 0px; width: 415px; padding: 1px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\">Rating Painful or Unstable Scars</span></span></a></span></div></td></tr><tr><td style=\"height: 0px; width: 84px; text-align: center; padding: 1px;\">4</td><td style=\"height: 0px; width: 415px; padding: 1px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\">Rating Specific Skin Conditions</span></span></a></span></div></td></tr></tbody></table></div><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><div class=\"ng-scope\"></div><div class=\"ng-scope\"><br/> <span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">1<a id=\"1\" name=\"1\">.</a>  General Principles for Rating Skin Disorders and Scars </span></span></h2><div class=\"ng-scope\"></div><div class=\"ng-scope\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains general principles for rating skin disorders and scars, including</span></span></div><ul><li><div><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">applying alterative rating criteria in evaluating skin conditions</span></span></a></div></li><li><div><a href=\"#1b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">separate evaluations for multiple skin disorders using the general rating formula</span></span></a></div></li><li><div><a href=\"#1c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">example of separate evaluations using the general rating formula</span></span></a></div></li><li><div><a href=\"#1d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">separate evaluation using the general rating formula based on medication criteria</span></span></a></div></li><li><div><a href=\"#1e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">single evaluations using the general rating formula for multiple skin disorders</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1f\" target=\"_self\">systemic therapy such as corticosteroids or other immunosuppressive drugs</a></span></span></div></li><li><div><a href=\"#1g\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">exposed body area</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1h\" target=\"_self\">application of the bilateral factor for skin conditions to include scarring</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1i\" target=\"_self\">revisions of the skin rating schedule</a>.</span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Change Date</strong></span></span></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">November 19, 2018</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.1.a<a id=\"1a\" name=\"1a\">.</a>  Applying Alternative Rating Criteria in Evaluating Skin Conditions</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118</a> offers variable methods to evaluate a skin condition, assign a single evaluation using the criteria that results in the highest rating.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example</em></strong>:  Under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118 diagnostic code (DC) 7806</a>, dermatitis is to be rated using the general rating formula for the skin.  Within the general rating formula, skin conditions are rated on either skin involvement/type of treatment or as disfigurement of the head, face, or neck or scars, depending upon the predominant disability.  For examination findings of dermatitis involving at least 5 percent, but less than 20 percent, of the entire body (a 10-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118 DC 7806</a>) and scarring that is noncompensable under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=957928142474523656b12619c9067a49&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118 DC 7800</a> through <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=957928142474523656b12619c9067a49&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118 DC 7805</a>, a single evaluation of 10 percent is warranted under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118 DC 7806</a>.  Assigning an evaluation for dermatitis based on percentage of involvement of the entire body and a separate evaluation based on the residual scarring amounts to pyramiding.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on avoidance of pyramiding, see </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.14</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2.b</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\">V.iii.10.1.b<a id=\"1b\" name=\"1b\">.</a> Separate Evaluations for Multiple Skin Disorders Using the General Rating Formula</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 523px; vertical-align: top; padding: 0px;\"><div><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\">When evaluating separately diagnosed skin conditions and the predominant disability requires evaluation under the general rating formula for the skin, separate evaluations for each diagnosis are permissible when the evaluation is based on disability due solely to the individual diagnosis.</span></span></div><div></div><div><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\">However, when it is most advantageous and allows for maximized benefits, multiple skin disorders evaluated under the same criteria may be assigned a single disability evaluation as discussed in <a href=\"#1e\" target=\"_self\">M21-1, Part V, Subpart iii, 10.1.e</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\">V.iii.10.1.c<a id=\"1c\" name=\"1c\">.</a> Separate Evaluations Using the General Rating Formula</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 523px; padding: 0px;\"><div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">A Veteran diagnosed with multiple skin conditions may receive separate evaluations using the general rating formula for the skin based on the percentage of exposed areas affected by each skin condition when</span></span></div><ul><li><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">separate areas of skin are involved, and</span></span></li><li><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">the medical evidence clearly indicates that the percentages affected are due solely to each individual diagnosis.</span></span></li></ul><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Example</em></strong>:  The medical evidence clearly indicates that skin condition X alone affects 6 percent of the exposed skin, while skin condition Y alone affects 12 percent of the exposed skin.  The area affected by each skin disability is entirely separate.  In this scenario, separate evaluations may be assigned.</span></span></div><div></div></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><em>Important</em></strong>:</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">The evidence <em>must</em> identify which residual disability is due to which individual skin condition.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">It may be necessary to request clarification from an examiner to identify the percentage of exposed skin affected only by one skin condition versus the other skin condition.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">If an examiner cannot provide separate percentages due solely to each skin condition, separate evaluations cannot be granted using those criteria alone.  If two or more skin conditions involve the same area of skin, assign the highest evaluation based on the combined area of involvement.</span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\">This guidance applies equally to evaluations based on the percentage of the entire body affected as well.</span></span></span></div></li></ul><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\"><em><strong>Reference</strong></em>:  For more information on assigning a single evaluation for multiple skin disabilities in order to maximize benefits, see <a href=\"#1e\" target=\"_self\">M21-1, Part V, Subpart iii, 10.1.e</a>.</span></span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\">V.iii.10.1.d<a id=\"1d\" name=\"1d\">.</a> Separate Evaluations Using the General Rating Formula Based on Medication Criteria</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 523px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If the same medication(s) is/are used to treat each skin condition, separate evaluations may not be assigned unless alternative criteria are used to establish the disability evaluation for the separately evaluated skin condition(s) and separate areas of the skin are affected.<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example</em></strong>:  The Veteran has dermatitis of the neck involving at least 5 percent but less than 20 percent of exposed body area.  The Veteran also has psoriasis on the knees involving less than 5 percent of total body area.  Both conditions were treated with oral corticosteroids for a period of less than 6 weeks over the past 12-month period.  Separate 10-percent disability evaluations may be assigned.  Assign a 10-percent evaluation for dermatitis based on exposed area affected, and assign a separate 10-percent evaluation for psoriasis treated with oral steroids<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">.</span></span></span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>:  The decision maker should assign separate evaluations in a manner that provides the most advantageous rating for the Veteran.</span></span></span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\">V.iii.10.1.e<a name=\"1e\">.</a>  Single Evaluations Using the General Rating Formula for Multiple Skin Disorders</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">A Veteran diagnosed with multiple skin conditions that are evaluated using the general rating formula for the skin based on the percentage of total body area or exposed areas affected may receive a single evaluation when</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluating the disabilities together allows for maximization of benefits, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the symptoms of and/or area affected by the multiple disabilities cannot be separated, as is directed by <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=28e1bccb346ce0cea97b58b931a4dcba&amp;mc=true&amp;node=se38.1.4_114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.14</a>. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example 1</em></strong>:  </span></span>A Veteran has service-connected (SC) dermatitis that affects areas of the arms, covering 10 percent of the entire body area.  The Veteran also has SC tinea corporis affecting the groin and upper legs, covering 10 percent of the entire body area.  Different topical medications are used to treat each disability.  Evaluated individually, each skin disorder warrants a separate 10-percent evaluation under the general rating formula for the skin.  As the disabilities combine to affect a total 20 percent of the entire body and do not affect the same area of the body, a single 30-percent evaluation for dermatitis and tinea corporis may be assigned under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=28e1bccb346ce0cea97b58b931a4dcba&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7806-7813</a>.  In this case, the single evaluation is assigned to maximize benefits since assignment of separate 10-percent evaluations would be a lesser benefit.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example 2</em></strong>:  A Veteran has SC dermatitis and eczema.  Both disabilities affect the hands, covering a total of three percent of exposed body area.  The examiner is unable to differentiate the percent of body area affected by each disorder.  The same topical treatment is used for both conditions.  A single zero percent disability evaluation must be assigned since the evaluation of the same manifestation under different diagnoses must be avoided. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When the Veteran has multiple SC skin disorders and maximization of benefits via assignment of a single evaluation appears possible but the examination results do not provide the specific measurements of affected body area, request a medical opinion to determine the actual percentage of body area affected. </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When analysis shows that benefits maximization is possible with the assignment of a single disability evaluation, enter the disabilities as a single disorder in the Evaluation Builder.  For example, using the facts from <em>Example 1</em> above, choose the predominant diagnosis and enter the single 20-percent finding for the percentage of body area affected.  This Evaluation Builder workaround must be utilized until updates are made for this functionality. </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\">V.iii.10.1.f<a id=\"1f\" name=\"1f\">.</a>  Systemic Therapy Such as Corticosteroids or Other Immunosuppressive Drugs</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 523px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The term systemic therapy that is contained in the general rating formula for the skin and in certain additional DCs under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=620d5aa7f88e8f447f93865ae93f16ca&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118</a> refers to treatment that is administered through any route (orally, injection, suppository, intranasally) other than the skin. Medications that are applied topically (directly to the skin), including topical corticosteroids or immunosuppressives, are not considered systemic for Department of Veterans Affairs (VA) purposes.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>:  </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When there is a question as to whether drug treatment is systemic therapy for rating purposes, request clarification from a VA or other licensed medical professional.</span></span></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The changes to <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=620d5aa7f88e8f447f93865ae93f16ca&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118</a> effective on August 13, 2018, preclude any consideration of topical therapy, irrespective of the extent of application to the body, as systemic therapy.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">For claims filed prior to August 13, 2018, where the skin condition is evaluated under the <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=38a0e444593a5bf4ff9c057a89a6bfa9&amp;pitd=20180810&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">historical 38 CFR 4.118</a>, medications that are applied topically (directly to the skin), including topical corticosteroids or immunosuppressives, are generally not considered systemic for VA purposes.  Under the historical rating criteria, a topical corticosteroid may only be considered systemic therapy where it is administered on such a large scale over the body that it affects the body as a whole. </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If the evidence suggests that a skin disability is treated so extensively with a topical corticosteroid that it may be consistent with systemic therapy, refer the case to an appropriate dermatology specialist for an opinion addressing whether the topical corticosteroid is used so extensively on the body that it may be considered systemic therapy.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If the matter cannot be resolved after obtaining the medical opinion, refer the case to Compensation Service for an advisory opinion.</span></span></div></li></ul></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example</em></strong>:  A Veteran is SC for dermatitis herpetiformis. Medical evidence shows she was treated with oral Dapsone for 7 weeks during the past 12-month period.  An evaluation of 30 percent is warranted for treatment with systemic therapy for a total duration of six weeks or more, but not constantly, during the past 12-month period.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on  </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the meaning of “such as” in the rating schedule, see <a articleid=\"554400000014772\" articlename=\"Mauerhan v. Principi, Oct 30, 2002, 16 Vet.App. 436\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014772/Mauerhan-v-Principi-Oct-30-2002-16-VetApp-436\"><em>Mauerhan v. Principi</em></a>, 16 Vet.App. 436 (2002), and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">determining whether topical corticosteroids can be considered systemic under historical rating criteria, see </span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000069850\" articlename=\"Johnson v. Shulkin, July 14, 2017, 862 F. 3d 1351 (Fed. Cir. 2017)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000069850/Johnson-v-Shulkin-July-14-2017-862-F-3d-1351-Fed-Cir-2017\"><em>Johnson v. Shulkin</em></a>, 862 F.3d 1351 (2017), and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000096584\" articlename=\"Burton v. Wilkie, Sep 28, 2018, 30 Vet.App. 286\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000096584/Burton-v-Wilkie-Sep-28-2018-30-VetApp-286\"><em>Burton v. Wilkie</em></a>, No. 16-2307 (2018), and </span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">requesting advisory opinions, see <a articleid=\"554400000177996\" articlename=\"M21-1, Part X, Subpart v, Chapter 1, Section A  - Compensation Service and Pension and Fiduciary (P&amp;F) Service Guidance\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177996/M21-1-Part-X-Subpart-v-Chapter-1-Section-A-Compensation-Service-and-Pension-and-Fiduciary-PF-Service-Guidance\">M21-1, Part X, Subpart v, 1.A.2</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.1.g<a id=\"1g\" name=\"1g\">.</a>  Exposed Body Area</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When evaluating disabilities under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118</a>, <em>exposed areas</em> as referenced in evaluation criteria refer to the face, neck, and hands. </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.1.h<a id=\"1h\" name=\"1h\">.</a>  Application of the Bilateral Factor to Evaluations for Skin Conditions to Include Scarring</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The bilateral factor under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_126&amp;rgn=div8\" target=\"_blank\">38 CFR 4.26</a> only applies to skin conditions rated based on the skin evaluation criteria under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DCs 7801 or 7802</a> as the evaluation criteria and notes provided by these DCs specifically address entitlement to separate evaluations for multiple extremity involvement.  The bilateral factor may also be for application for conditions rated under a DC with evaluation criteria not considering skin involvement (such as when the predominant disability is that pertaining to musculoskeletal impairment).  Do not apply the bilateral factor to DCs for skin conditions to include scars that are</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">based on whole-body involvement</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">based on number of debilitating episodes, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">specific to the head, face, and/or neck. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Examples</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The bilateral factor is not for application to <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7804</a> as painful or unstable scars are not evaluated separately under this DC.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">For ratings based on malignant skin neoplasms under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7818</a>, the bilateral factor is not for application when assigning a 100 percent evaluation for active malignancy/treatment for six months following cessation.  However, when evaluating based on residuals following the six-month period, the bilateral factor may or may not apply depending on whether the residual is being evaluated based on a qualifying DC.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.1.i<a id=\"1i\" name=\"1i\">.</a>  Revisions of the Skin Rating Schedule</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Regulatory revisions to the rating schedule are generally not liberalizing, including those revisions to <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118</a> effective on October 23, 2008, and August 13, 2018.  <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=c3424561ad9c39f877a2d58085f41e51&amp;mc=true&amp;node=se38.1.3_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 3.114(a)</a> does not apply because the regulatory change did not characterize the change as a liberalizing change of law or VA issue. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on assigning effective dates based on regulatory updates to the rating schedule, see <a articleid=\"554400000180492\" articlename=\"M21-1, Part V, Subpart ii, Chapter 4, Section A - Effective Dates\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180492/M21-1-Part-V-Subpart-ii-Chapter-4-Section-A-Effective-Dates\">M21-1, Part V, Subpart ii, 4.A.6</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><h2 class=\"ng-scope\"> <br/> </h2><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">2<a id=\"2\" name=\"2\">.</a>  Rating Scars or Other Disfigurement of the Head, Face, or Neck</span></strong></span></h2><div class=\"ng-scope\"></div><div class=\"ng-scope\"><br/> </div><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information on rating scars or other disfigurement of the head, face, or neck, including</span></span></div><ul><li><div><a href=\"#2a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">considering color photographs in evaluating scars or other disfigurement</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#2b\" target=\"_self\">multiple scars</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#2c\" target=\"_self\">tissue loss of the auricle, anatomical loss of the eye, and other disabling effects</a></span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">, and</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#2d\" target=\"_self\">whether scars or disfigurement of the head, face, or neck are part of the claim</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">August 13, 2018</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\">V.iii.10.2.a<a id=\"2a\" name=\"2a\">.</a>  Considering Color Photographs in Evaluating Scars or Other Disfigurement</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When an examination report indicates that photographs have been taken of a scar or skin condition, consider the photographs when evaluating the condition. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on procedures for handling photographs associated with skin and scars examinations, see <a articleid=\"554400000180516\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section B - Examination Sufficiency for Specific Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180516/M21-1-Part-IV-Subpart-i-Chapter-3-Section-B-Examination-Sufficiency-for-Specific-Disabilities\">M21-1, Part IV, Subpart i, 3.B.1.k</a>.</span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.10.2.b<a id=\"2b\" name=\"2b\">.</a>  Evaluating Multiple Scars</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Scars of the head, face, or neck are evaluated based on characteristics of disfigurement.  For all characteristics of disfigurement included in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7800</a> that are evaluated based on size of area affected, the area affected by multiple scars may be added together to meet the total area criteria for the characteristic of disfigurement.  The characteristics of disfigurement criteria that can be met by adding the area affected by multiple scars include</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">length</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hypo- or hyper-pigmentation</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">abnormal skin texture</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">absence of underlying soft tissue, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">induration or inflexibility. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Exception</em></strong>:  Multiple scars may <strong><em>not</em></strong> be added together to meet the width of scarring requirement.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Examples</em></strong>: </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Two scars, one measuring two inches in length and the other measuring three inches in length, may be combined to meet the requirement of a scar five inches or more in length to qualify as a characteristic of disfigurement. </span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In contrast, two scars, one measuring .13 inches in width and the other measuring .12 inches in width, may not be combined to meet the requirement of a scar at least one-quarter inch wide at the widest part.</span></span></span></span></div></li></ul></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span> <span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">multiple painful or unstable scars, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7804</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">multiple burn or other scars not of the head, face, or neck, see</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7801</a>, Notes 1 and 2, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7802</a>, Notes 1 and 2. </span></span></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.2.c<a id=\"2c\" name=\"2c\">.</a>  Evaluating Tissue Loss of the Auricle, Anatomical Loss of the Eye, and Other Disabling Effects</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Evaluate tissue loss of the auricle under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_187&amp;rgn=div8\" target=\"_blank\">38 CFR 4.87, DC 6207</a></span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> and anatomical loss of the eye under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6061 or 6063</a>, </span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">as appropriate.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When the evidence of record shows disabling effects other than disfigurement, such as pain, instability, or muscle/nerve injury, separately evaluate under the appropriate DC based on the functional impairment shown by the record.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on evaluating scars and what qualifies as a characteristic of disfigurement, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.10.2.d<a id=\"2d\" name=\"2d\">.</a> Whether Scars or Disfigurement of the Head, Face, or Neck Are Part of the Claim</span></span></h3></td><td style=\"height: 9px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If a scar or other disfigurement of the head, face, or neck is noted on VA examination or in other evidence of record but has not been expressly claimed, whether to put it at issue and decide it as part of the claim depends on whether </span><span style=\"font-family: arial, helvetica, sans-serif\">the scar is considered within scope of the pending claim</span><span style=\"font-family: arial, helvetica, sans-serif\">. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">within scope determinations</span><span style=\"font-family: arial, helvetica, sans-serif\">, see <a articleid=\"554400000180486\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section A - Determining the Issues\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180486/M21-1-Part-V-Subpart-ii-Chapter-3-Section-A-Determining-the-Issues\">M21-1, Part V, Subpart ii, 3.A.1.c</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">soliciting a claim for unclaimed chronic disabilities shown by the evidence, see <a articleid=\"554400000174879\" articlename=\"M21-1, Part II, Subpart iii, Chapter 2, Section G - Requests for Application and Claims Solicitation\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000174879/M21-1-Part-II-Subpart-iii-Chapter-2-Section-G-Requests-for-Application-and-Claims-Solicitation\">M21-1, Part II, Subpart iii, 2.G.2</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></p><div class=\"ng-scope\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">3<a id=\"3\" name=\"3\">.</a>  Rating Painful or Unstable Scars</span></strong></span></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span><br/> </p><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information on rating painful or unstable scars, including</span></span></div><ul><li><div><a href=\"#3a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">assigning a separate disability evaluation for functional impairment due to a painful scar</span></span></a></div></li><li><div><a href=\"#3b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">objective evidence of a painful scar</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#3c\" target=\"_self\">definition of an unstable scar</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#3d\" target=\"_self\">evaluating unstable and painful scars</a></span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#3e\" target=\"_self\">whether painful or unstable scars are part of the claim</a>. </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">August 13, 2018</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.3.a<a id=\"3a\" name=\"3a\">.</a>  Assigning a Separate Disability Evaluation for Functional Impairment Due to a Painful Scar</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">A separate disability evaluation for a painful scar under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=957928142474523656b12619c9067a49&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7804</a> may be assigned when the evidence demonstrates functional impairment that is</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">distinct and separate from the functional impairment addressed by another DC, and is not</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">duplicative of or overlapping with the symptomatology addressed under another DC. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example</em></strong>:  A separate 10-percent evaluation for disfigurement under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=957928142474523656b12619c9067a49&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7800</a> may be assigned in addition to a 10-percent evaluation for painful scars under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=957928142474523656b12619c9067a49&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7804</a> and a 10-percent evaluation for facial injury interfering with mastication under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=1e74586da6b31d65c7de6f6d54aa0b09&amp;mc=true&amp;node=se38.1.4_173&amp;rgn=div8\" target=\"_blank\">38 CFR 4.73, DC 5325</a> as each evaluation is based on distinct and separate functional impairment and, therefore, provisions related to pyramiding are not violated.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  An evaluation under </span><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=957928142474523656b12619c9067a49&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7800</a></span><span style=\"font-family: arial , helvetica , sans-serif\"> is entirely cosmetic in nature.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">assigning a separate disability evaluation for functional impairment due to a painful scar, see </span><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000066775\" articlename=\"Esteban v. Brown, February 25, 1994, 6 Vet.App. 259 (1994)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000066775/Esteban-v-Brown-February-25-1994-6-VetApp-259-1994\"><em>Esteban v. Brown</em></a>, 6 Vet.App. 259 (1994)</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating scars in the presence of muscle conditions, see </span><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000014422\" articlename=\"M21-1, Part V, Subpart iii, Chapter 1, Section E - Muscle Injuries\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014422/M21-1-Part-V-Subpart-iii-Chapter-1-Section-E-Muscle-Injuries\">M21-1, Part V, Subpart iii, 1.E.2.h</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">pyramiding, see</span></span><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=23a806dc944e2adac34fc99baacf25ec&amp;mc=true&amp;node=se38.1.4_114&amp;rgn=div8\">38 CFR 4.14</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2.b</a>.</span></span></div></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"height: 348px; width: 654px; border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.3.b<a id=\"3b\" name=\"3b\">.</a>  Objective Evidence of a Painful Scar</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7804</a>, an evaluation of 10 percent is assigned for one or two scars that are unstable <strong><em>or</em></strong> painful.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">  </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Do not establish a compensable evaluation for a painful scar unless there is some objective indication supporting subjective reports of pain or tenderness.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The physical examination section (for the trunk/extremities or the head/face/ neck as applicable) of the <a href=\"http://vbacoweb03.dva.va.gov/bl/21/DBQ/docs/InternalDBQs/Scars.pdf\" target=\"_blank\"><em>Scars/Disfigurement Disability Benefits Questionnaire</em></a> (DBQ) asks the examiner if scars are tender to palpation and, if yes, to check the box.  If the examiner checks that a scar is tender to palpation consider pain to be objectively demonstrated.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example</em></strong>:  On VA examination, the Veteran gave a history of a painful scar of the trunk.  On the DBQ, in the physical examination of the trunk and extremities, the examiner checked that the trunk scar was tender to palpation.  Accept that the scar is objectively painful.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example</em></strong>:  On VA examination, the Veteran gave a history of a painful scar of the left arm.  On the DBQ, in the physical examination of the trunk and extremities, the examiner did not check that the scar was tender to palpation.  Do not accept that the scar is objectively painful.</span></span></div></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.3.c<a id=\"3c\" name=\"3c\">.</a>  Definition:  Unstable Scar</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">An <strong><em>unstable scar</em></strong> is a scar in which, for any reason, there is frequent loss of covering of skin over the scar. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on unstable scars, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=957928142474523656b12619c9067a49&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7804</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 155px; width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.3.d<a id=\"3d\" name=\"3d\">.</a>  Evaluating Unstable and Painful Scars</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 155px; width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When a scar is <strong><em>both</em></strong> unstable and painful, add 10 percent to the evaluation that would otherwise be assigned based on the total number of unstable or painful scars under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7804</a>.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example</em></strong>:  If a VA examination notes one right knee arthroscopy scar that is described as unstable and painful, the proper evaluation based on the painful and unstable scar is 20 percent.  Under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7804</a>, one painful scar is entitled to an evaluation of 10 percent.  Since the painful scar is also noted to be unstable, an additional 10 percent is added to that evaluation to arrive at an overall evaluation of 20 percent.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><div class=\"ng-scope\"><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 151px; width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\">V.iii.10.3.e<a id=\"3e\" name=\"3e\">.</a> Whether Painful or Unstable Scars Are Part of the Claim</span></span></h3></td><td style=\"height: 9px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"height: 151px; width: 516px; padding: 0px;\"><div><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\">If a painful or unstable scar is noted on VA examination or in other evidence of record but has not been expressly claimed, whether to put it at issue and decide it as part of the claim depends on whether the scar is considered within scope of the pending claim. </span></span></div><div><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></div><div><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">within scope determinations, see <a articleid=\"554400000180486\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section A - Determining the Issues\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180486/M21-1-Part-V-Subpart-ii-Chapter-3-Section-A-Determining-the-Issues\">M21-1, Part V, Subpart ii, 3.A.1.c</a>, and</span></span></div></li><li><div><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">soliciting a claim for unclaimed chronic disabilities shown by the evidence, see <a articleid=\"554400000174879\" articlename=\"M21-1, Part II, Subpart iii, Chapter 2, Section G - Requests for Application and Claims Solicitation\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000174879/M21-1-Part-II-Subpart-iii-Chapter-2-Section-G-Requests-for-Application-and-Claims-Solicitation\">M21-1, Part II, Subpart iii, 2.G.2</a>. </span></span></span></div></li></ul></td></tr></tbody></table><div style=\"margin-left: 85pt\"><hr/></div><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></p></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">4<a id=\"4\" name=\"4\">.</a>  Rating Specific Skin Conditions</span></strong></span></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><p> <br/> </p><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information on rating specific skin conditions, including</span></span></div><ul><li><a href=\"#4a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">SC for male pattern baldness or androgenetic alopecia</span></span></a></li><li><div><a href=\"#4b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">assigning multiple evaluations due to hair loss</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#4c\" target=\"_self\">evaluating mycosis fungoides</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">November 19, 2018</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.4.a<a id=\"4a\" name=\"4a\">.</a> SC for Male Pattern Baldness or Androgenetic Alopecia</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Do not grant SC for</span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">male pattern baldness, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">androgenetic alopecia.  </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  VA classifies these conditions as congenital or developmental abnormalities.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Important</em></strong>:  While SC is not warranted for alopecia of androgenetic origin, VA recognizes hair loss due to scarring alopecia and alopecia areata under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DCs 7830 and 7831</a>, as disabilities for which SC is warranted if first manifest in service.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on congenital or developmental abnormalities, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=29884efaf774e1afa8af847c677700d0&amp;mc=true&amp;node=se38.1.4_19&amp;rgn=div8\" target=\"_blank\">38 CFR 4.9</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000180485\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section E - Service Connection (SC) for Congenital, Developmental, or Hereditary Disorders\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180485/M21-1-Part-V-Subpart-ii-Chapter-2-Section-E-Service-Connection-SC-for-Congenital-Developmental-or-Hereditary-Disorders\">M21-1, Part V, Subpart ii, 2.E</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.4.b<a id=\"4b\" name=\"4b\">.</a> Assigning Multiple Evaluations Due to Hair Loss</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Assign separate evaluations for</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">complete loss of the eyebrows and eyelashes due to injury, burns, or local disease under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6023</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">complete loss of the eyelashes due to injury, burns, or local disease under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6024</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">loss of all body hair due to alopecia areata or an analogous condition under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7831</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.10.4.c<a id=\"4c\" name=\"4c\">.</a>  Evaluating Mycosis Fungoides</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Mycosis fungoides is a cutaneous manifestation of T-cell lymphoma that typically presents as some form of skin lesion and rarely progresses beyond the skin. </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">For rating purposes, it is not considered a systemic malignancy.  As such, with the revised skin rating schedule, mycosis fungoides should be evaluated under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=9e0a0bdd13b193fb9886d6348e53d490&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7822</a>. </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If the condition progresses to a lymphoma with appropriate diagnosis, such as Non-Hodgkin’s lymphoma (active disease/active treatment phase), it would warrant an evaluation under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=9e0a0bdd13b193fb9886d6348e53d490&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7715</a>.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Prior to the rating schedule change of August 13, 2018, mycosis fungoides was evaluated as <em>either</em></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">a skin malignancy if manifestations were cutaneous lesions only and treatment was confined to only</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">localized topical therapy, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">surgical excision (wide local excision or less extensive excision), or</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">non-Hodgkin’s lymphoma if manifestations were indicative of systemic disease with treatment consistent with systemic malignancy. </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 11px\"><a articleid=\"554400000180513\" articlename=\"M21-1, Part V, Subpart iii, Chapter 9 - Hematologic and Lymphatic Systems\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180513/M21-1-Part-V-Subpart-iii-Chapter-9-Hematologic-and-Lymphatic-Systems\">&lt;-- Previous Section</a>  <a articleid=\"554400000180518\" articlename=\"M21-1, Part V, Subpart iii, Chapter 11 - Endocrine Conditions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180518/M21-1-Part-V-Subpart-iii-Chapter-11-Endocrine-Conditions\">Next Section --&gt;</a></span></span><span style=\"font-size: 16px\"><strong><span style=\"font-family: arial , helvetica , sans-serif\"> </span></strong></span></p><p class=\"ng-scope\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://vbacoweb03.dva.va.gov/bl/21/DBQ/docs/InternalDBQs/Scars.pdf",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=1e74586da6b31d65c7de6f6d54aa0b09&mc=true&node=se38.1.4_173&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=23a806dc944e2adac34fc99baacf25ec&mc=true&node=se38.1.4_114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=29884efaf774e1afa8af847c677700d0&mc=true&node=se38.1.4_19&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&node=se38.1.4_1118&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&node=se38.1.4_114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&node=se38.1.4_126&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&node=se38.1.4_179&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=3448d4d006e9807a14305759baa1ccc8&node=se38.1.4_187&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=620d5aa7f88e8f447f93865ae93f16ca&mc=true&node=se38.1.4_1118&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=957928142474523656b12619c9067a49&mc=true&node=se38.1.4_1118&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=c3424561ad9c39f877a2d58085f41e51&mc=true&node=se38.1.3_1114&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=28e1bccb346ce0cea97b58b931a4dcba&mc=true&node=se38.1.4_1118&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=28e1bccb346ce0cea97b58b931a4dcba&mc=true&node=se38.1.4_114&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=38a0e444593a5bf4ff9c057a89a6bfa9&pitd=20180810&node=se38.1.4_1118&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=9e0a0bdd13b193fb9886d6348e53d490&mc=true&node=se38.1.4_1118&rgn=div8"
  ],
  "scraped_at": "2025-06-16T22:45:44.520859",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180518/M21-1-Part-V-Subpart-iii-Chapter-11-Endocrine-Conditions"
}